Infectious diseases are increasing rapidly all over the world and are among the top causes of death. Unnecessary use of antibiotics, especially the increasing problem of resistance cause difficulties in treatments with antimicrobial drugs. It’s critical to discover new natural compounds for antibiotics. In this regard, mushrooms have proved to be particularly interesting sources of antimicrobial compounds. Therefore, it will be more possible to discover potential antibiotic candidates from mushrooms.
Lifeasible provides one-stop preclinical research services for antibiotic drug development of mushroom extracts. From the extraction and separation of antibacterial active compounds to preclinical mechanism research, we can provide technical support for the development of your drug.
A variety of organic compounds in mushrooms are the material basis for their antibacterial effects. The hydroxyl groups in phenols and phenolic acids determine their toxicity to microorganisms. Quinones can irreversibly react with nucleophilic amino acids in proteins, resulting in protein inactivation and loss of function. Other chemicals, such as p-coumaric acid, affect cell membrane permeability, DNA binding capacity, and cell function by slowing or inhibiting it. Natural extract antimicrobials change the pH of the cytoplasm and have the capacity to damage microbe membranes through their processes. Moreover, mushroom extracts with antimicrobial activity generally involve interactions with bacterial cell wall polypeptides, membrane-bound enzymes, and surface-exposed adhesins to kill bacteria.
Fig. 1 Antimicrobial mechanism of mushroom extracts. (Agarwal A, et al., 2023)
Lifeasible provides research services for the development of antibiotic drugs from mushroom extracts. Our services include but are not limited to the following:
Provide extraction and separation services of target substances according to your needs to speed up your experimental process.
We provide the following antibacterial or antibacterial test methods to meet your scientific research needs. The selection of test methods for samples in different states is as follows. If you have other related test needs, you can contact us for a detailed consultation.
We offer services to assay the activity of mushroom extracts against the following bacteria and their resistant bacteria, the types of bacteria we can test include but are not limited to the following:
Acinetobacter baumannii
Bacillus subtilis
Bacillus cereus
Escherichia coli
Staphylococcus aureus
Salmonella typhi
Enterococcus faecalis
Helicobactor pylori
Klebsiella pneumoniae
Klebsiella typhimurium
Salmonella enteritidis
Micrococcus luteus
Pseudomonas aeruginosa
Plesiomonas shigelloides
Proteous vulgaris
Streptococcus pyogenes
We perform molecular docking studies on active compounds against target proteins involved in the antibacterial mechanism of action to evaluate their affinity to bacterial proteins and determine the mechanism and target of these compounds.
Fig. 2 The process of the MIC/MBC test.
Lifeasible provides one-stop preclinical research services for antibiotic drug development of mushroom extracts. To help people better understand the health-promoting properties of mushrooms and enhance their use to help prevent and treat human disease. If you are interested in our research services, please contact us for a more detailed description of our services.
Reference
For research use only, not for clinical use.